RxDoctor Payments Data

Jeneth Aquino

Family · Nashville, TNNPI 1659679884

Payments from drug & device makers

$10,379in general payments, 2019–2025

Across 48 payments — averaging $216.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • E.r. Squibb & Sons, L.L.C.$562
  • Daiichi Sankyo Inc.$469
  • Johnson & Johnson$364
  • AbbVie$343
  • Seagen Inc.$262
  • plus $982 from 10 others

What the payments were for

  • Consulting fees$5625%
  • Speaking & faculty fees$7207%
  • Travel & lodging$6,48863%
  • Food & beverage$2,43623%
  • Education$1732%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,379 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$41,280
Medicare patients
207
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$41,065
EliquisApixaban23$19,208
Oxycodone Hcl52$617
Ondansetron OdtOndansetron16$440
Prochlorperazine Maleate37$416
Dexamethasone39$341
Ondansetron Hcl38$279
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$261
Olanzapine38$232
Lidocaine-PrilocaineLidocaine/Prilocaine12$149
Lorazepam15$105
Omeprazole16$76
Spironolactone14$75
Gabapentin11$73
Metoclopramide Hcl15$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$343$41,06513 claims
PfizerEliquis$100$19,20823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →